Neuravi, a Galway, Ireland-based company dedicated to improve clinical outcomes for stroke patients, raised €15m in venture debt financing.
IPF Partners provided the financial resources.
The company intends to use the funds to invest in U.S. commercialization and stroke treatment portfolio expansion.
Led by Eamon Brady, CEO, Neuravi designs, develops and manufactures innovative medical devices for the treatment of acute ischemic stroke. Neuravi is exclusively focused on acute ischemic stroke.
Its EmboTrap® Revascularization Device is engineered to restore blood flow to the brain by retrieving clot with a proprietary dual-layer stent-like structure. The device’s integrated distal protection zone is designed to reduce the risk of clot fragmentation during retrieval, which could cause additional harm to the patient.
The device is available in Europe to treat patients with acute ischemic stroke and is currently available for investigational use only in the U.S. under the ARISE II clinical trial.